Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer

Cancer

Volumn 117, Issue 20, 2011, Pages 4651-4658

  Hayn, Matthew H ^a   Orom, Heather ^b   Shavers, Vickie L ^c   Sanda, Martin G ^d,e   Glasgow, Mark ^b   Mohler, James L ^a   Underwood III, Willie ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

African Americans; European Continental Ancestry Group; Hispanic Americans; lymph node excision; prostate; prostatic cancer; Surveillance, Epidemiology, and End Results

Indexed keywords

ADULT; AGED; ARTICLE; ASIAN; CANCER GRADING; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HISPANIC; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; TUMOR DIFFERENTIATION;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PELVIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 80053926862     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26103     Document Type: Article

References (45)

1. Jemal A SR, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 275-340.
2. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101: 3-27. (Pubitemid 38812419)
3. Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B,. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995; 274: 1599-1605.
4. Robbins AS, Yin D, Parikh-Patel A,. Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995-2004. Am J Epidemiol. 2007; 166: 71-78. (Pubitemid 47234297)
5. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B,. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13: 93-100.
6. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT,. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004; 171: 1504-1507. (Pubitemid 38365406)
7. Richert-Boe KE, Weinmann S, Shapiro JA, et al. Racial differences in treatment of early stage prostate cancer. Urology. 2008; 71: 1172-1176.
8. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the Prostate Cancer Outcomes Study. J Gen Intern Med. 2003; 18: 845-853. (Pubitemid 37281780)
9. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF,. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 1171-1176. (Pubitemid 39647061)
10. Schapira MM, McAuliffe TL, Nattinger AB,. Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care. 1995; 33: 1079-1088.
11. Shavers VL, Brown M, Klabunde CN, et al. Race/ethnicity and the intensity of medical monitoring under "watchful waiting" for prostate cancer. Med Care. 2004; 42: 239-250.
12. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB,. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113. (Pubitemid 34437345)
13. Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003; 95: 1702-1710. (Pubitemid 37509079)
14. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE,. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/mL undergoing radical prostatectomy for prostate cancer? Eur Urol. 2006; 50: 272-279. (Pubitemid 44038073)
15. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol. 2003; 169: 849-854. (Pubitemid 36188105)
16. Heidenreich A, Ohlmann CH, Polyakov S,. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol. 2007; 52: 29-37. (Pubitemid 46803038)
17. Mohler JL,. The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
18. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy. Part II: prostate cancer staging and post-treatment follow-up. Urology. 2001; 57: 225-229. (Pubitemid 32140793)
19. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472-479. (Pubitemid 43779173)
20. Joslyn SA, Konety BR,. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006; 68: 121-125. (Pubitemid 44037727)
21. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC,. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004; 172: 1840-1844. (Pubitemid 39363069)
22. Chin JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J. 2010; 4: 13-25.
23. Narain V, Tiguert R, Banerjee M, Grignon D, Wood DP, Powell IJ,. Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer. J Urol. 2001; 165: 474-477. (Pubitemid 32060439)
24. Nielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006; 176: 515-519. (Pubitemid 43927881)
25. Rosser CJ, Kuban DA, Lee SJ, et al. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc. 2004; 96: 939-944. (Pubitemid 38823508)
26. Bishoff JT, Reyes A, Thompson IM, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology. 1995; 45: 270-274.
27. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA,. No difference in 6-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology. 2004; 63: 528-531.
28. Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999; 162: 394-397. (Pubitemid 29434347)
29. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995; 274: 1277-1281.
30. Fiscella K, Franks P, Gold MR, Clancy CM,. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000; 283: 2579-2584. (Pubitemid 30324204)
31. Nelson TD,. Handbook of Prejudice, Stereotyping, and Discrimination. New York: Psychology Press; 2009.
32. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW,. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003; 81: 21-31. (Pubitemid 37108437)
33. Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML,. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005; 23: 9079-9088.
34. Spencer BA, Miller DC, Litwin MS, et al. Variations in quality of care for men with early stage prostate cancer. J Clin Oncol. 2008; 26: 3735-3742.
35. Tajfel H,. Social psychology of intergroup relations. Annu Rev Psychol. 1982; 33: 1-39.
36. Gaertner SL, Dovidio JF,. The subtlety of white racism, arousal, and helping behavior. J Pers Soc Psychol. 1977; 35: 691-707.
37. Chapman LJ, Chapman JP,. Genesis of popular but erroneous psychodiagnostic observations. J Abnorm Psychol. 1967; 72: 193-204.
38. Dovidio JF, Gaertner SL,. Aversive racism and selection process. In:, Zanna MP, ed. Advances in Experimental Social Psychology. San Diego, CA: Academic Press; 2004: 1-52.
39. Greenwald AG, McGhee DE, Schwartz JLK,. Measuring individual differences in implicit cognition: the implicit association test. J Pers Soc Psychol. 1998; 74: 1464-1480. (Pubitemid 128658112)
40. Dovidio JF, Gaertner SL,. Aversive racism. In:, Mark PZ, ed. Advances in Experimental Social Psychology. San Diego, CA: Academic Press; 2004: 1-52. (Pubitemid 39753654)
41. Uhlmann E, Dasgupta N, Elgueta A, Greenwald AG, Swanson J,. Subgroup prejudice based on skin color among Hispanics in the United States and Latin America. Soc Cogn. 2002; 20: 198-226. (Pubitemid 36742906)
42. Son Hing LS, Li W, Zanna MP,. Inducing hypocrisy to reduce prejudicial responses among aversive racists. J Exp Soc Psychol. 2002; 38: 71-78.
43. Correll J, Park B, Judd CM, Wittenbrink B,. The police officer's dilemma: using ethnicity to disambiguate potentially threatening individuals. J Pers Soc Psychol. 2002; 83: 1314-1329.
44. Green AR, Carney DR, Pallin DJ, et al. Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med. 2007; 22: 1231-1238. (Pubitemid 47247298)
45. Sabin JA, Nosek BA, Greenwald AG, Rivara FP,. Physicians' implicit and explicit attitudes about race by MD race, ethnicity, and gender. J Health Care Poor Underserved. 2009; 20: 896-913.